Monday Morning Pre-Market Insights: Celldex Therapeutics, Inc. (CLDX), Celladon Corp (CLDN), CTI BioPharma Corp (CTIC), TG Therapeutics Inc (TGTX)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose more than +10% in pre-market trading to $32.01 after the biopharmaceutical company released data on a study indicating that an experimental vaccine was effective in patients with brain cancer. The 12-month consensus target price on TipRanks for Celldex is $37.23, marking a 29% potential upside based on current levels. Out of the 4 analysts who cover Celldex stock, all of them have open Buy positions.
Celladon Corp (NASDAQ:CLDN) shares are up more than +11% to $2.58 in pre-market trading following an announcement of approval for a strategic plan to begin the process to seek an acquisition or a partnership. The Board of Directors believes this is the best way to maximize value for shareholders. According to TipRanks, two top ranked analysts have Hold ratings on the stock with an average price target of $3, representing a nearly 30% upside from where the stock is currently trading.
CTI BioPharma Corp (NASDAQ:CTIC) shares increased +7.7% in pre-market trading to $2.09 on Monday morning after the biopharmaceutical company announced clinically meaningful results for its Phase 3 Pacritinib Study results, a therapy for a rare bone marrow cancer. According to TipRanks, Debjit Chattopadhyay of Roth Capital reiterated a Buy rating on CTIC in late March as he expected positive results from the test.
TG Therapeutics Inc (NASDAQ:TGTX) shares are up +7.75% to $16.96 after the biopharmaceutical company posted positive clinical results from two ongoing studies of a combination drug and an independent drug. The combination was well tolerated in all 55 patients enrolled in the study. CEO Michael Weiss noted, “We continue to be impressed with the safety and efficacy profile of TGR-1202, as a single agent, and in combination with TG-1101, and we believe the high level of activity and our differentiated safety profile seen to date.” According to TipRanks, two top-ranked analysts currently have Buy ratings on the stock with an average price target of $27.50, marking a 74% upside from where the stock is currently trading.